Cumulative proportion of the incidence of hospitalization owing to fractures.

Multivariate-adjusted hazard ratios of hospitalization owing to fractures associated with angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use considering patients with different levels of parathyroid hormone, sex, or systolic blood pressure.

Suguru Yamamoto (721661)
Ryo Kido (721662)
Yoshihiro Onishi (721663)
Shingo Fukuma (685099)
Tadao Akizawa (316095)
Masafumi Fukagawa (721664)
Junichiro J. Kazama (721665)
Ichiei Narita (156924)
Shunichi Fukuhara (316094)

April 2015

The hazard ratio was obtained from the Cox regression model adjusted for the distribution of age;...

Prevalence of statin and angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blocker (ARB) users in the pneumonia and control groups.

Jiunn-Horng Kang (427929)
Li-Ting Kao (409065)
Herng-Ching Lin (284636)
Ta-Jung Wang (5465276)
Tsung-Yeh Yang (2194069)

June 2018

Prevalence of statin and angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor ...

Subgroup Analysis of ACEI and ARB: Regular versus Potentially Contaminated Heparin.

Heiko A. Kaiser (622132)
Arbi Ben Abdallah (176559)
Nan Lin (26755)
Bethany R. Tellor (622133)
Mohammad Helwani (622134)
Jennifer R. Smith (368977)
Marc R. Moon (622135)
Michael S. Avidan (622136)

August 2014

ACEI indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker....

Crude, case-mix-adjusted, and multivariate-adjusted hazard ratios of hospitalization owing to fractures associated with angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use.

Suguru Yamamoto (721661)
Ryo Kido (721662)
Yoshihiro Onishi (721663)
Shingo Fukuma (685099)
Tadao Akizawa (316095)
Masafumi Fukagawa (721664)
Junichiro J. Kazama (721665)
Ichiei Narita (156924)
Shunichi Fukuhara (316094)

April 2015

The covariates included in each analytical model for adjustment were as follows: case-mix, age, s...

Demographic and clinical characteristics of study cohorts.

Sina Moeller (551677)
Pietro A. Canetta (551678)
Annette K. Taylor (422746)
Carolina Arguelles-Grande (551679)
Holly Snyder (195958)
Peter H. Green (551680)
Krzysztof Kiryluk (156863)
Armin Alaedini (296768)

April 2014

1ACEI: Angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.</p

Medication use.

Colin D. Chue (136552)
Nadezhda A. Wall (319159)
Nicola J. Crabtree (319161)
Daniel Zehnder (291721)
William E. Moody (319163)
Nicola C. Edwards (319164)
Richard P. Steeds (319166)
Jonathan N. Townend (319167)
Charles J. Ferro (319168)

February 2013

Data are frequency (percentage). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin ...

Summary of patient selection.

Hon-Yen Wu (286645)
Chiao-Ling Peng (503342)
Pei-Chun Chen (194576)
Chih-Kang Chiang (135324)
Chee-Jen Chang (287558)
Jenq-Wen Huang (135317)
Yu-Sen Peng (315725)
Yu-Kang Tu (41946)
Tzong-Shinn Chu (141730)
Kuan-Yu Hung (286650)
Kuo-Liong Chien (73583)

May 2017

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.</p

Medication use of study groups.

Martijn A. M. den Dekker (501762)
Marjan Zwiers (501763)
Edwin R. van den Heuvel (501764)
Lisanne C. de Vos (501765)
Andries J. Smit (371032)
Clark J. Zeebregts (501766)
Matthijs Oudkerk (79015)
Rozemarijn Vliegenthart (79011)
Joop D. Lefrandt (424871)
Douwe J. Mulder (418146)

December 2013

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.</p

Concomitant medications use within 90 days of index discharge.

Szu-Heng Wang (761539)
Dong-Yi Chen (319219)
Yu-Sheng Lin (68720)
Chun-Tai Mao (651349)
Ming-Lung Tsai (651350)
Ming-Jer Hsieh (103100)
Chung-Chuan Chou (600857)
Ming-Shien Wen (319221)
Chun-Chieh Wang (600856)
I-Chang Hsieh (103109)
Kuo-Chun Hung (410861)
Tien-Hsing Chen (331860)

June 2015

Values are n (%); ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor b...

Patient's medication.

Hiroki Sugiyama (351211)
Kazufumi Nakamura (336712)
Hiroshi Morita (124362)
Satoshi Akagi (351212)
Yoshinori Tani (351213)
Yusuke Katayama (351214)
Nobuhiro Nishii (351215)
Toru Miyoshi (341854)
Satoshi Nagase (351216)
Kunihisa Kohno (351217)
Kengo Fukushima Kusano (351218)
Tohru Ohe (351219)
Junko Kurokawa (253979)
Tetsushi Furukawa (253981)
Hiroshi Ito (297745)

February 2013

ACEI/ARB: Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.</p

Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study - Fig 3

Hon-Yen Wu (286645)
Chiao-Ling Peng (503342)
Pei-Chun Chen (194576)
Chih-Kang Chiang (135324)
Chee-Jen Chang (287558)
Jenq-Wen Huang (135317)
Yu-Sen Peng (315725)
Yu-Kang Tu (41946)
Tzong-Shinn Chu (141730)
Kuan-Yu Hung (286650)
Kuo-Liong Chien (73583)

May 2017

Hazard ratios and 95% confidence intervals comparing ACEI therapy with ARB therapy for study o...

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers

Kara Kew (13073589)
Amelia Betson (13058094)
Kara Anderson (13058328)
F Sepetavc (13810264)
James Gaston (13075839)
Mark Kotowicz (13079622)
W H Liao (13421304)
M Henneberg (9886355)
Julie Pasco (13077054)

September 2022

Medications used to treat hypertension may affect fracture risk. This study investigated fracture ri...

Prescription of the recommended therapy.

Myriam L. Montminy (2156071)
Valerie Gauvin (2156065)
Stephane Turcotte (2156077)
Alain Milot (62252)
Yvan Douville (2156068)
Isabelle Bairati (2156074)

February 2016

ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary a...

Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

Holloway-Kew, Kara L
Betson, Amelia G
Anderson, Kara B
Gaston, James
Kotowicz, Mark A
Liao, Wan-Hui
Henneberg, Maciej
Pasco, Julie A

December 2021

Angiotensin-converting enzyme inhibitor use in women was associated with lower femoral neck and lumb...

Use of Medications.

Hsiao-Han Wang (429124)
Chi-Chih Hung (106523)
Daw-Yang Hwang (343487)
Mei-Chuan Kuo (106525)
Yi-Wen Chiu (106535)
Jer-Ming Chang (106541)
Jer-Chia Tsai (106527)
Shang-Jyh Hwang (5312)
Julian L. Seifter (429125)
Hung-Chun Chen (106543)

July 2013

Data expressed as mean ± standard deviation, median (interquartile range) or percentage.AC...

Multivariate-adjusted hazard ratios of hospitalization owing to fractures associated with angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use considering patients with different levels of parathyroid hormone, sex, or systolic blood pressure.

Suguru Yamamoto (721661)
Ryo Kido (721662)
Yoshihiro Onishi (721663)
Shingo Fukuma (685099)
Tadao Akizawa (316095)
Masafumi Fukagawa (721664)
Junichiro J. Kazama (721665)
Ichiei Narita (156924)
Shunichi Fukuhara (316094)

April 2015

The hazard ratio was obtained from the Cox regression model adjusted for the distribution of age;...

Prevalence of statin and angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blocker (ARB) users in the pneumonia and control groups.

Jiunn-Horng Kang (427929)
Li-Ting Kao (409065)
Herng-Ching Lin (284636)
Ta-Jung Wang (5465276)
Tsung-Yeh Yang (2194069)

June 2018

Prevalence of statin and angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor ...

Subgroup Analysis of ACEI and ARB: Regular versus Potentially Contaminated Heparin.

Heiko A. Kaiser (622132)
Arbi Ben Abdallah (176559)
Nan Lin (26755)
Bethany R. Tellor (622133)
Mohammad Helwani (622134)
Jennifer R. Smith (368977)
Marc R. Moon (622135)
Michael S. Avidan (622136)

August 2014

ACEI indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker....

Crude, case-mix-adjusted, and multivariate-adjusted hazard ratios of hospitalization owing to fractures associated with angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use.

Suguru Yamamoto (721661)
Ryo Kido (721662)
Yoshihiro Onishi (721663)
Shingo Fukuma (685099)
Tadao Akizawa (316095)
Masafumi Fukagawa (721664)
Junichiro J. Kazama (721665)
Ichiei Narita (156924)
Shunichi Fukuhara (316094)

April 2015

The covariates included in each analytical model for adjustment were as follows: case-mix, age, s...

Demographic and clinical characteristics of study cohorts.

Sina Moeller (551677)
Pietro A. Canetta (551678)
Annette K. Taylor (422746)
Carolina Arguelles-Grande (551679)
Holly Snyder (195958)
Peter H. Green (551680)
Krzysztof Kiryluk (156863)
Armin Alaedini (296768)

April 2014

1ACEI: Angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.</p

Medication use.

Colin D. Chue (136552)
Nadezhda A. Wall (319159)
Nicola J. Crabtree (319161)
Daniel Zehnder (291721)
William E. Moody (319163)
Nicola C. Edwards (319164)
Richard P. Steeds (319166)
Jonathan N. Townend (319167)
Charles J. Ferro (319168)

February 2013

Data are frequency (percentage). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin ...

Summary of patient selection.

Hon-Yen Wu (286645)
Chiao-Ling Peng (503342)
Pei-Chun Chen (194576)
Chih-Kang Chiang (135324)
Chee-Jen Chang (287558)
Jenq-Wen Huang (135317)
Yu-Sen Peng (315725)
Yu-Kang Tu (41946)
Tzong-Shinn Chu (141730)
Kuan-Yu Hung (286650)
Kuo-Liong Chien (73583)

May 2017

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.</p

Medication use of study groups.

Martijn A. M. den Dekker (501762)
Marjan Zwiers (501763)
Edwin R. van den Heuvel (501764)
Lisanne C. de Vos (501765)
Andries J. Smit (371032)
Clark J. Zeebregts (501766)
Matthijs Oudkerk (79015)
Rozemarijn Vliegenthart (79011)
Joop D. Lefrandt (424871)
Douwe J. Mulder (418146)

December 2013

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.</p

Concomitant medications use within 90 days of index discharge.

Szu-Heng Wang (761539)
Dong-Yi Chen (319219)
Yu-Sheng Lin (68720)
Chun-Tai Mao (651349)
Ming-Lung Tsai (651350)
Ming-Jer Hsieh (103100)
Chung-Chuan Chou (600857)
Ming-Shien Wen (319221)
Chun-Chieh Wang (600856)
I-Chang Hsieh (103109)
Kuo-Chun Hung (410861)
Tien-Hsing Chen (331860)

June 2015

Values are n (%); ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor b...

Patient's medication.

Hiroki Sugiyama (351211)
Kazufumi Nakamura (336712)
Hiroshi Morita (124362)
Satoshi Akagi (351212)
Yoshinori Tani (351213)
Yusuke Katayama (351214)
Nobuhiro Nishii (351215)
Toru Miyoshi (341854)
Satoshi Nagase (351216)
Kunihisa Kohno (351217)
Kengo Fukushima Kusano (351218)
Tohru Ohe (351219)
Junko Kurokawa (253979)
Tetsushi Furukawa (253981)
Hiroshi Ito (297745)

February 2013

ACEI/ARB: Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.</p

Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study - Fig 3

Hon-Yen Wu (286645)
Chiao-Ling Peng (503342)
Pei-Chun Chen (194576)
Chih-Kang Chiang (135324)
Chee-Jen Chang (287558)
Jenq-Wen Huang (135317)
Yu-Sen Peng (315725)
Yu-Kang Tu (41946)
Tzong-Shinn Chu (141730)
Kuan-Yu Hung (286650)
Kuo-Liong Chien (73583)

May 2017

Hazard ratios and 95% confidence intervals comparing ACEI therapy with ARB therapy for study o...

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers

Kara Kew (13073589)
Amelia Betson (13058094)
Kara Anderson (13058328)
F Sepetavc (13810264)
James Gaston (13075839)
Mark Kotowicz (13079622)
W H Liao (13421304)
M Henneberg (9886355)
Julie Pasco (13077054)

September 2022

Medications used to treat hypertension may affect fracture risk. This study investigated fracture ri...

Prescription of the recommended therapy.

Myriam L. Montminy (2156071)
Valerie Gauvin (2156065)
Stephane Turcotte (2156077)
Alain Milot (62252)
Yvan Douville (2156068)
Isabelle Bairati (2156074)

February 2016

ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary a...

Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

Holloway-Kew, Kara L
Betson, Amelia G
Anderson, Kara B
Gaston, James
Kotowicz, Mark A
Liao, Wan-Hui
Henneberg, Maciej
Pasco, Julie A

December 2021

Angiotensin-converting enzyme inhibitor use in women was associated with lower femoral neck and lumb...

Use of Medications.

Hsiao-Han Wang (429124)
Chi-Chih Hung (106523)
Daw-Yang Hwang (343487)
Mei-Chuan Kuo (106525)
Yi-Wen Chiu (106535)
Jer-Ming Chang (106541)
Jer-Chia Tsai (106527)
Shang-Jyh Hwang (5312)
Julian L. Seifter (429125)
Hung-Chun Chen (106543)

July 2013

Data expressed as mean ± standard deviation, median (interquartile range) or percentage.AC...

Multivariate-adjusted hazard ratios of hospitalization owing to fractures associated with angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use considering patients with different levels of parathyroid hormone, sex, or systolic blood pressure.

Suguru Yamamoto (721661)
Ryo Kido (721662)
Yoshihiro Onishi (721663)
Shingo Fukuma (685099)
Tadao Akizawa (316095)
Masafumi Fukagawa (721664)
Junichiro J. Kazama (721665)
Ichiei Narita (156924)
Shunichi Fukuhara (316094)

April 2015

The hazard ratio was obtained from the Cox regression model adjusted for the distribution of age;...

Prevalence of statin and angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blocker (ARB) users in the pneumonia and control groups.

Jiunn-Horng Kang (427929)
Li-Ting Kao (409065)
Herng-Ching Lin (284636)
Ta-Jung Wang (5465276)
Tsung-Yeh Yang (2194069)

June 2018

Prevalence of statin and angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor ...

Subgroup Analysis of ACEI and ARB: Regular versus Potentially Contaminated Heparin.

Heiko A. Kaiser (622132)
Arbi Ben Abdallah (176559)
Nan Lin (26755)
Bethany R. Tellor (622133)
Mohammad Helwani (622134)
Jennifer R. Smith (368977)
Marc R. Moon (622135)
Michael S. Avidan (622136)

August 2014

ACEI indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker....

Cumulative proportion of the incidence of hospitalization owing to fractures.

Abstract

Extracted data

Cumulative proportion of the incidence of hospitalization owing to fractures.

Abstract

Extracted data

Related items

Related items